10x Genomics Q1 2026: Flat Revenue, IP Settlements Mask Core Weakness

What happened

10x Genomics reported Q1 2026 results that continue the trend of flat core product revenue, with total revenue again boosted by non-recurring IP settlement income. Spatial consumables grew at a high-teens pace, but this was offset by double-digit declines in Chromium consumables and a >30% drop in instrument revenue. Gross margins remained in the high-60s artificially propped up by license and royalty revenue, while operating losses persisted on a normalized basis. Management reiterated its 2026 guidance of $610-$630 million in revenue, implying no organic growth acceleration, and cited ongoing NIH funding uncertainty as a headwind. The market has yet to price in the structural dependence on one-time IP income and the lack of sustainable growth from core products.

Implication

The Q1 2026 results validate the bearish thesis: core products and services revenue remains stagnant, with no sign of an inflection in instrument or Chromium consumables growth. Spatial consumables alone cannot drive the overall business to profitability given the deepening declines elsewhere. Non-recurring IP settlements have provided a temporary cushion but are finite; as they roll off, margins and cash flow will deteriorate unless organic growth materializes. Management's flat guidance for full-year 2026 leaves no upside catalyst on the horizon, while NIH funding risk (~20-25% of revenue) remains a dark cloud. With the stock trading at ~3.5x EV/sales and no credible path to self-funding, downside to $14 or lower is likely if core trends persist.

Thesis delta

The Q1 2026 results reinforce the existing sell thesis with no evidence of organic growth acceleration; the reliance on IP income has become a structural crutch rather than a temporary bridge. The thesis shifts from cautiously monitoring a potential turnaround to actively expecting further downside, as management's lack of concrete guidance for Chromium or instrument recovery points to a prolonged stagnation. Any hopes of a bull case driven by new product adoption must be abandoned until clear quarter-over-quarter progress in core revenue is demonstrated.